Streetbeat News

Analyst Ratings

CKPT

NTRA

PINS

TDUP

Insiders at Pinterest, Checkpoint Therapeutics, ThredUp, and Natera have recently sold shares. Pinterest's stock was positively reviewed by Keybanc, Checkpoint announced a $14 million offering, ThredUp reported disappointing Q3 results, and Natera acquired assets from Invitae.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 2:42 pm

NWPP

SKYE

VANI

Insiders at Skye Bioscience, New Peoples Bankshares, and Vivani Medical have recently made significant stock purchases. Skye Bioscience saw a 10% owner acquire over 5 million shares, with an analyst initiating coverage with an Overweight rating and a $12 price target. New Peoples Bankshares director bought nearly 90,000 shares as the stock gained 11% over six months. Vivani Medical's director purchased 100 shares amid a report of a wider-than-expected quarterly loss.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 2:30 pm

LCTX

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Lineage Cell Therapeutics (LCTX) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:27 pm

META

Goldman Sachs analyst Eric Sheridan has maintained a Buy rating on Meta Platforms (NASDAQ:META) and increased the price target from $414 to $500.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:27 pm

MNDY

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Monday.Com (NASDAQ:MNDY) and maintained a $250 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:20 pm

COHR

Needham analyst James Ricchiuti reiterated a Buy rating on Coherent (NYSE:COHR) and maintained a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:18 pm

REGN

BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1055 to $1082.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:15 pm

ABBV

Raymond James analyst Gary Nachman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $181 to $189 as of 4th February 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:15 pm

RNR

BMO Capital analyst Michael Zaremski has maintained an Outperform rating on RenaissanceRe Holdings (NYSE:RNR) and increased the price target from $216 to $295.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:13 pm